Allergen immunotherapy for IgE-mediated food allergy:A systematic review and meta-analysis by Nurmatov, Ulugbek et al.
Syddansk Universitet
Allergen immunotherapy for IgE-mediated food allergy
Nurmatov, Ulugbek; Dhami, S; Arasi, S.; Pajno, Giovanni Battista; Fernandez-Rivas,
Monserrat; Muraro, A; Roberts, G; Akdis, C ; Alvaro-Lozano, Montserrat; Beyer, K; Bindslev-
Jensen, Carsten; Burks, Wesley; Du Toit, G; Ebisawa, M.; Eigenmann, P.; Knol, Edward;
Makela, Mika; Nadeau, Kari Christine; O'Mahony, L; Papadopoulos, N; Poulsen, L. K.;
Sackesen, Cansin; Sampson, H.; Santos, A F; van Ree, Ronald; Timmermans, F; Sheikh, A
Published in:
Allergy
DOI:
10.1111/all.13124
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Nurmatov, U., Dhami, S., Arasi, S., Pajno, G. B., Fernandez-Rivas, M., Muraro, A., ... Sheikh, A. (2017). Allergen
immunotherapy for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy, 72(8),
1133–1147. DOI: 10.1111/all.13124
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
REVIEW ARTICLE
Allergen immunotherapy for IgE-mediated food allergy: a
systematic review and meta-analysis
U. Nurmatov1, S. Dhami2 , S. Arasi3,4, G. B. Pajno3, M. Fernandez-Rivas5, A. Muraro6,
G. Roberts7,8, C. Akdis9, M. Alvaro-Lozano10, K. Beyer11,12, C. Bindslev-Jensen13, W. Burks14,
G. du Toit15, M. Ebisawa16, P. Eigenmann17, E. Knol18, M. Makela19, K. C. Nadeau20 ,
L. O’Mahony21 , N. Papadopoulos22, L. K. Poulsen23, C. Sackesen24, H. Sampson25,
A. F. Santos26, R. van Ree27, F. Timmermans28 & A. Sheikh29
1Division of Population Medicine Neuadd Meirionnydd, School of Medicine, Cardiff University, Cardiff; 2Evidence-Based Health Care Ltd,
Edinburgh, UK; 3Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy; 4Molecular Allergology and
Immunomodulation-Department of Pediatric Pneumology and Immunology, Charite Medical University, Berlin, Germany; 5Allergy
Department, Hospital Clınico San Carlos, IdISSC, Madrid, Spain; 6Department of Women and Child Health, Food Allergy Referral Centre
Veneto Region, Padua General University Hospital, Padua, Italy; 7The David Hide Asthma and Allergy Research Centre, St Mary’s Hospital,
Newport, Isle of WIght, UK; 8NIHR Respiratory Biomedial Research Unit and Faculty of Medicine, University of Southampton, Southampton,
UK; 9Swiss Institute for Allergy and Asthma Research, Davos Platz, Switzerland; 10Paediatric Allergy and Clinical Immunology Section,
Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain; 11Pediatric Pneumology and Immunology, Charite
Universit€atsmedizin, Berlin, Germany; 12Icahn School of Medicine at Mount Sinai, New York, NY, USA; 13Department of Dermatology and
Allergy Centre, Odense University Hospital, Odense, Denmark; 14Department of Pediatrics, School of Medicine, University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA; 15Department of Paediatric Allergy, Division of Asthma, Allergy and Lung Biology, MRC & Asthma
Centre in Allergic Mechanisms of Asthma, King’s College London, St Thomas NHS Foundation Trust, London, UK; 16Department of Allergy,
Clinical Research Center for Allergy & Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan; 17University Hospitals of
Geneva and Medical School of the University of Geneva, Geneva, Switzerland; 18Department of Immunology and Department of
Dermatology & Allergology, University Medical Center, Utrecht, The Netherlands; 19Skin and Allergy Hospital, Helsinki University Hospital,
Helsinki, Finland; 20Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Stanford University, Stanford, CA, USA;
21Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland; 22Department of Allergy, 2nd Pediatric
Clinic, University of Athens, Athens, Greece; 23Department of Allergy Clinic, Copenhagen University Hospital, Gentofte, Denmark;
24Department of Pediatric Allergist, Koc¸ University Hospital, I˙stanbul, Turkey; 25World Allergy Organization (WAO), Mount Sinai Hospital, NY,
USA; 26Department of Paediatric Allergy, Division of Asthma, Allergy and Lung Biology, King’s College London, Guy’s and St Thomas’
Hospital NHS Foundation Trust, London, UK; 27Department of Otorhinolaryngology, Academic Medical Center, Amsterdam; 28Nederlands
Anafylaxis Netwerk – European Anaphylaxis Taskforce, Dordrecht, The Netherlands; 29Allergy and Respiratory Research Group, Centre of
Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
To cite this article: Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A, Roberts G, Akdis C, Alvaro-Lozano M, Beyer K, Bindslev-Jensen C,
Burks W, du Toit G, Ebisawa M, Eigenmann P, Knol E, Makela M, Nadeau KC, O’Mahony L, Papadopoulos N, Poulsen LK, Sackesen C, Sampson H, Santos AF,
van Ree R, Timmermans F, Sheikh A. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017; 72: 1133–
1147.
Keywords
allergen immunotherapy; food allergy;
safety; desensitization; sustained
unresponsiveness.
Correspondence
Dr. Sangeeta Dhami, Evidence-Based Health
Care Ltd, Edinburgh, UK.
E-mail: sangeetadhami@hotmail.com
Accepted for publication 3 January 2017
DOI:10.1111/all.13124
Edited by: Bodo Niggemann
Abstract
Background: The European Academy of Allergy and Clinical Immunology
(EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-
mediated Food Allergy. To inform the development of clinical recommendations,
we sought to critically assess evidence on the effectiveness, safety and cost-effec-
tiveness of AIT in the management of food allergy.
Methods: We undertook a systematic review and meta-analysis that involved
searching nine international electronic databases for randomized controlled trials
(RCTs) and nonrandomized studies (NRS). Eligible studies were independently
assessed by two reviewers against predefined eligibility criteria. The quality of
studies was assessed using the Cochrane Risk of Bias tool for RCTs and the
Cochrane ACROBAT-NRS tool for quasi-RCTs. Random-effects meta-analyses
were undertaken, with planned subgroup and sensitivity analyses.
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Results: We identified 1814 potentially relevant papers from which we selected 31
eligible studies, comprising of 25 RCTs and six NRS, studying a total of 1259
patients. Twenty-five trials evaluated oral immunotherapy (OIT), five studies inves-
tigated sublingual immunotherapy, and one study evaluated epicutaneous
immunotherapy. The majority of these studies were in children. Twenty-seven stud-
ies assessed desensitization, and eight studies investigated sustained unresponsive-
ness postdiscontinuation of AIT. Meta-analyses demonstrated a substantial benefit
in terms of desensitization (risk ratio (RR) = 0.16, 95% CI 0.10, 0.26) and sug-
gested, but did not confirm sustained unresponsiveness (RR = 0.29, 95% CI 0.08,
1.13). Only one study reported on disease-specific quality of life (QoL), which
reported no comparative results between OIT and control group. Meta-analyses
revealed that the risk of experiencing a systemic adverse reaction was higher in those
receiving AIT, with a more marked increase in the risk of local adverse reactions.
Sensitivity analysis excluding those studies judged to be at high risk of bias demon-
strated the robustness of summary estimates of effectiveness and safety of AIT for
food allergy. None of the studies reported data on health economic analyses.
Conclusions: AIT may be effective in raising the threshold of reactivity to a range
of foods in children with IgE-mediated food allergy whilst receiving (i.e. desensiti-
zation) and post-discontinuation of AIT. It is, however, associated with a modest
increased risk in serious systemic adverse reactions and a substantial increase in
minor local adverse reactions. More data are needed in relation to adults, long
term effects, the impact on QoL and the cost-effectiveness of AIT.
Food allergy may result in considerable morbidity and, in
some cases, mortality (1). Epidemiological studies have
demonstrated that the prevalence and severity of food allergy
may be increasing, particularly in children (2–8). Food aller-
gies can be divided into IgE-mediated acute allergic reactions
manifesting as urticaria, vomiting, wheezing and anaphylaxis,
and non-IgE-mediated food allergy which results from
delayed, cell-mediated reactions. This systemic review is
focused on IgE-mediated reactions.
Food allergies can be associated with significant reduc-
tion in disease-specific quality of life (QoL) – both of indi-
viduals who suffer from food allergy and their family
members (9, 10). At present, avoidance measures are the
cornerstone of management (11). Difficulties in avoiding
responsible food allergens can, however, result in accidental
exposure and the risk of triggering potentially life-threaten-
ing anaphylaxis. Of concern is the increasing numbers of
people being seen in emergency departments or who are
hospitalized because of food-induced anaphylaxis (12, 13).
Individuals with food allergy may therefore need to carry
adrenaline (epinephrine) auto-injectors in order to self-man-
age anaphylaxis. This approach is, however, perceived as
restrictive and still leaves patients at risk if accidental expo-
sure occurs (2, 7, 8).
Allergen immunotherapy (AIT) has been used for over a
century to treat those with food allergy (14). It involves
repeated administration of gradually increasing doses of the
antigens to which individuals are allergic in the hope of
allowing safe exposure to the food(s) in question. Whilst AIT
has become an established treatment regimen in relation to
the management of, for example, pollen and insect venom
allergy (15), it has yet to become established in the routine
management of food allergy.
The European Academy of Allergy and Clinical
Immunology (EAACI) is in the process of developing the
EAACI Guidelines for AIT, and this systematic review and
meta-analysis is one of five interlinked assessments of the
current evidence base in relation to evaluating AIT for the
treatment of food allergy, allergic rhinoconjunctivitis,
venom allergy, allergic asthma and allergy prevention, which
will be used to inform development of clinical recommenda-
tions. The focus of this review, which builds on our previ-
ous related reviews (16, 17), is to assess the effectiveness,
safety and cost-effectiveness of AIT in the management of
IgE-mediated food allergy.
Methods
Details of the methods employed in this review, including
search terms and filters, databases searched, inclusion and
exclusion criteria, data extraction and quality appraisal, have
been previously reported (18). We therefore confine ourselves
here to a synopsis of the methods employed.
Search strategy
Nine international databases were searched for published
material: Cochrane Library, which includes CENTRAL [Tri-
als, Methods studies, Health Technology Assessments
(HTA), Economic Evaluation database (EED)]; MEDLINE,
EMBASE, ISI Web of Science, TRIP and CINAHL. The
search strategy was developed on OVID MEDLINE and
then adapted for the other databases (see Appendix S1:
search strategies 1 and 2). Our database searches covered
from inception to 31 March 2016. The bibliographies of all
eligible studies were scrutinized to identify additional possible
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studies. No language restrictions were imposed and where
necessary manuscripts were translated into English.
Inclusion criteria
Patient characteristics
We focused on studies conducted on children and adults of
any age with a clinician-diagnosed IgE-mediated food allergy
to milk, eggs, peanuts, tree nuts and other foods with confir-
mation of allergic status through positive skin prick tests,
specific-IgE and/or food challenge tests.
Interventions of interest and comparators
This review focused on AIT for different allergens, that is
milk, eggs, tree nuts, peanuts and other foods, administered
through the following routes: oral (OIT), sublingual (SLIT)
and epicutaneous (EPIT). We were interested in studies
comparing food allergy AIT with placebo or routine care
(i.e. adrenaline auto-injector with or without antihistamines)
or no treatment.
Outcomes
Our primary outcomes of interest were as follows: (i) desensi-
tization (i.e. the ability to safely consume foods containing
the allergen in question whilst on AIT); (ii) sustained unre-
sponsiveness (i.e. the ability to safely consume foods contain-
ing the allergen in question after discontinuing AIT) at food
challenge; and (iii) changes in disease-specific QoL using a
validated instrument. Secondary outcome measures of inter-
est were safety as assessed by local and systemic reactions in
accordance with the World Allergy Organization’s (WAO)
grading system of side effects (19, 20); health economic
analysis from the perspective of the health system/payer as
reported in studies.
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Additional records identified 
through other sources
N = 4
Records after duplicates removed
N = 1695
Records screened
N = 1695
Records excluded
N = 1484
Abstracts assessed for 
eligibility
N = 211
Abstracts excluded
N = 138
Potential relevant studies 
included 
N = 75
Studies included in 
qualitative synthesis
N = 31 studies
(30 reports)
Exclusions after full text review N = 44 
• Conference papers = 40
• SCIT = 1
• Uncontrolled study = 1
• Case-control study = 1
• Immunological outcomes = 1
1 study from experts
Figure 1 PRISMA flow diagram.
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Study designs
We were interested in RCTs investigating the role of OIT,
SLIT or EPIT in children and adults with IgE-mediated
food allergy. However, given the likelihood that we would
find only a limited number of RCTs, we also searched
for nonrandomized studies (NRS), these including non-
randomized controlled clinical trials (CCTs), controlled
before-and-after (CBA) studies and interrupted time series
(ITS) analyses.
Study selection
All references were uploaded into the systematic review
software DistillerSR. Titles and abstracts of identified
Table 1 Description of the included studies (n = 31)
Study (first author,
year, country)
Food allergen (s) Route AIT
Cow’s milk
Hen’s
egg Peanut Hazelnut Peach Apple Fish Other(s) OIT SLIT EPIT
RCT (n = 25)
Anagnostou, 2014, UK X X
Burks, 2012, USA X X
Caminiti, 2009, Italy X X
Caminiti, 2015; Italy X X
Dello Iacono, 2013, Italy X X
Dupont, 2010, France X X
Enrique, 2005, Spain X X†
Escudero, 2015, Spain X X
Fernandez-Rivas, 2009, Spain X X‡
Fleischer, 2012, USA X X
Fuentes-Aparicio,
2013, Spain
X X
Kim, 2011, USA X X
Lee, 2013, Korea X X
Longo, 2008, Italy X X
Martorell, 2011, Spain X X
Meglio, 2013, Italy X X
Morisset, 2007, France‡‡ X X X
Pajno, 2010, Italy X X
Patriarca, 1998, Italy X X X X X
Salmivesi, 2012, Finland X X
Skripak, 2008, USA X X
Staden, 2007, Germany X X X
Tang, 2015, Australia X X††
Varshney, 2011, USA X X
CCT (n = 6)
Garcıa-Ara, 2013, Spain X X
Martınez-Botas, 2015, Spain X X
Mansouri, 2007, Iran X X
Patriarca, 2003, Italy X X X X X X X§ X
Patriarca, 2007, Italy X X X X X¶ X‡
Syed, 2014, USA X X
AE, adverse event; AIT, allergen-specific immunotherapy; DR-QoL, disease-related quality of life; LR, local reaction; NR, not reported; OIT,
oral immunotherapy; OFC, open food challenge; SLIT, sublingual immunotherapy; SR, systemic reaction.
†Sublingual-discharge technique.
‡Sublingual-swallow technique.
§Orange, corn, bean, lettuce.
¶Wheat, bean.
††AIT and probiotics.
‡‡One report that included two independent randomized controlled trials on cows’ milk and hens’ eggs.
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studies were checked and independently reviewed by two
researchers (UN, SD). The full text of all potentially eligi-
ble studies was assessed for eligibility against the eligibility
criteria (UN, SA). Any disagreements were resolved
through discussion, with SD or AS arbitrating if agreement
could not be reached.
Quality assessment strategy
The quality of included RCTs was independently assessed by
two reviewers (UN, SA) using the methods detailed in section
eight of the Cochrane Handbook for Systematic Reviews of
Interventions (21). Critical appraisal of quasi-RCTs, CCTs
Comparator Evidence of allergy (mandatory inclusion criteria) Clinical outcomes
Placebo
Routine
care
(food
avoidance) Desensitization
Sustained
unresponsiveness DR-QoL
Occurred
AEs / medi-
cation use
Clinical
history
SPT &/
or sIgE OFC SBPCFC DBPCFC SRs LRs
X X X X X X X X
X X X X X X X
X X X X X X X
X X X X X X X X
X X X X X X X
X X X X X X X
X X X X X X X
X X X X X X X
X X X X X X X
X X
X X X X X X X X
X X X X
X X X X X X X
X X X X X X X
X X X X X X
X X X X X X
X X X X X X X
X X X X X X X
X X X X X X
X X X X X X X X
X X X X X X
X X X X X X X
X X X X X X X X
X X X X X X
X X X X X X X
X X X X X X X X
X X X X X X X
X X X X X X X
X X X X X X X
X X X X X NR NR
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was undertaken using the Cochrane ACROBAT tool for
NRS (22). An overall assessment of quality for each trial
using these categories was arrived at through consensus dis-
cussion amongst reviewers.
Data extraction, analysis and synthesis
Data were independently extracted onto a customized data
extraction sheet in DistillerSR by two reviewers (UN, SA),
and any discrepancies were resolved by discussion or, if
agreement could not be reached, by arbitration by a third
reviewer (SD or AS).
Where possible and appropriate, data were synthesized
using random-effects meta-analyses following the prespecified
analysis plan. For the assessment of safety, as there were a
number of studies with zero reported outcomes, to facilitate
meta-analyses, we expressed safety data as the risk of not
experiencing a local or systemic reaction. All analyses were
undertaken using the software Comprehensive Meta-Analysis
(version 3).
Sensitivity, subgroup analyses and assessment for publication
bias
Sensitivity analyses were undertaken by focusing on results
from double-blind RCTs. Subgroup analyses were under-
taken to compare:
• Diagnosis of food allergy was confirmed by double-blind,
placebo-controlled, food challenge (DBPCFC) vs without
DBPCFC.
• Route of administration: OIT vs SLIT vs EPIT.
• Children (0–17 years) vs adults (≥18 years).
• Type of AIT protocol: conventional vs rush.
• Allergens used for AIT.
Where possible, publication bias was assessed through the
creation of funnel plots in Comprehensive Meta-Analysis
(version 3).
Registration and reporting of this systematic review
This systematic review was conducted and reported in accor-
dance with Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines. The protocol is
registered in PROSPERO (International Prospective Register
of Systematic Reviews) with registration number:
CRD42016039384.
Results
Our searches identified 1814 potentially relevant papers, from
which we identified 31 trials that satisfied our inclusion crite-
ria studying a total of 1259 patients (Fig. 1: PRISMA flow
diagram). There were 25 RCTs (23–46) and six NRS’, all of
which were CCTs (47–52). Twenty-five of these trials investi-
gated OIT (23–27, 30, 33, 35–50, 52), one epicutaneous
immunotherapy (EPIT) (28) and the remaining five investi-
gated SLIT (29, 31, 32, 34, 51). One report included two
independent RCTs on cow’s milk (CMA) and hen’s egg
(HEA) (39). Sixteen studies focused on CMA (25, 35–37, 39–
44, 47–51), 11 on HEA (24, 26, 27, 30, 33, 38, 39, 41, 44, 50,
51), seven on peanut (23, 32, 34, 45, 46, 50, 52), one hazelnut
(29), two peach (31, 50), three apple (41, 50, 51), three fish
(41, 50, 51) and two other studies focused on a variety of
food allergens including orange, corn, bean, lettuce (50),
wheat and bean (51) (see Table 1 and Appendix S2:
Table S1). The trials were undertaken in Italy (n = 9), Spain
(n = 7), the USA (n = 6), France (n = 3), Australia (n = 1),
Finland (n = 1), Germany (n = 1), Iran (n = 1), Korea
(n = 1) and the UK (n = 1).
Quality assessment
Quality assessment of these studies revealed that eight of the
RCTs were judged to be at low risk of bias (24, 26, 32, 34,
36, 40, 45, 46); a further five RCTs were judged as at unclear
risk of bias (28, 31, 33, 37, 43), and the remaining 12 RCTs
(23, 25, 27, 29, 30, 35, 38, 39, 41, 42, 44) were judged to be
at high risk of bias (see Appendix S3: Table S2). The six
CCTs (47–52) were all judged to be at moderate risk of bias
(see Appendix S4: Table S3).
Primary outcomes
Desensitization
Desensitization was assessed in 18 OIT RCTs (23–27, 33, 35–
43, 45, 46) and five OIT CCTs (47–51). There were also four
SLIT RCTs (29, 31, 32, 34) and one SLIT CCT (51) that
assessed desensitization. The efficacy of AIT was compared
with placebo in 12 studies, eight of which used OIT (24–26,
42, 43, 45, 46) and four of SLIT (29, 31, 32, 34); the other 17
studies, all of OIT, employed routine care (i.e. food avoid-
ance/strict elimination diet as the comparator) (27, 30, 33,
35–39, 41, 44, 47–52).
Meta-analysis was possible with data from 27 trials investi-
gating a total of 1171 subjects; this revealed a substantial bene-
fit with respect to desensitization: relative risk (RR) = 0.16,
95% CI 0.10, 0.26; see Fig. 2A (23–27, 29–41, 43, 44, 46–52).
Sensitivity analyses
Sensitivity analysis of the 21 RCTs, excluding the six CCTs,
also demonstrated a substantial benefit: RR = 0.21, 95% CI
0.13, 0.34; see Fig. 2B (23–27, 29–41, 43, 44, 46). A further
sensitivity analysis excluding all trials judged to be at high
risk of bias confirmed this substantial benefit: RR = 0.15,
95% CI 0.09, 0.25; see Fig. 2C (24, 26, 31–34, 36, 37, 40, 43,
46–52). A further sensitivity analysis excluding all trials
(whether OIT or SLIT) judged to be at high risk of bias
demonstrated a substantial average risk reduction (RR
OIT = 0.17, 95% CI 0.11, 0.26) (24, 26, 33, 36, 37, 40, 43,
46–50) and (RR SLIT = 0.31, 95% CI 0.10, 0.98) (31, 32, 34)
(see Appendix S5: Figs S1 and S2).
A final sensitivity analysis focusing on studies in which
desensitization was confirmed by DBPCFC after OIT or
SLIT also revealed substantial benefits (RR 0.15, 95% CI
0.09, 0.27; see Appendix S5: Fig. S3) (23, 25–27, 29–31,
35–41, 43, 44, 47–52).
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Subgroup analyses
• Subgroup analysis based on the route of administration of
AIT (OIT vs SLIT) revealed that both OIT (RR = 0.14,
95% CI 0.08, 0.24; see Fig. 3) (23–27, 30, 33, 35–41, 43, 44,
46–50, 52) and SLIT were effective (RR = 0.26, 95% CI
0.10, 0.64; see Fig. 4) (29, 31, 32, 34, 51).
• A subgroup analysis based on the age of the population
studied (children aged up to 18 years old, adults
≥18 years old and mixed population that included sub-
jects 0–55 years old) revealed a substantial average
risk reduction only for children and mixed popula-
tions, but not for adults (RR, children’s studies = 0.16,
95% CI 0.09, 0.27) (23–27, 30, 32–41, 43, 44, 46–49).
(RR, adults = 0.56, 95% CI 0.23, 1.36) (29, 31) (RR,
mixed population = 0.04, 95% CI 0.01, 0.19) (50–52) (see
Appendix S5: Figs S4–S6).
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
rao limit limit Control Experimental weight
Anagnostou 2014 0.017 0.001 0.277 0 / 46 24 / 39 2.25
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 2.29
Camini 2009 0.183 0.013 2.528 0 / 3 7 / 10 2.44
Camini 2015 0.011 0.000 1.952 0 / 14 16 / 17 0.77
Dello Lacono 2013 1.000 0.022 45.635 1 / 10 1 / 10 1.33
Enrique 2005 0.218 0.030 1.588 1 / 11 5 / 12 3.58
Escudero 2015 0.035 0.005 0.238 1 / 31 28 / 30 3.71
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 7.27
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 6.38
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 8.05
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 3.76
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 2.36
Lee 2013 0.045 0.003 0.688 0 / 12 14 / 16 2.31
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 2.23
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 2.31
Marnez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 2.36
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 8.06
Meglio 2013 0.250 0.070 0.897 2 / 10 8 / 10 5.65
Morisset 2007b 0.692 0.468 1.023 18 / 39 34 / 51 8.96
Pajno 2010 0.048 0.003 0.746 0 / 15 10 / 15 2.27
Patriarca 1998 0.055 0.004 0.826 0 / 10 12 / 14 2.32
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 2.30
Patriarca 2007 0.054 0.004 0.806 0 / 10 36 / 42 2.33
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 2.35
Staden 2007 0.722 0.347 1.504 7 / 21 12 / 26 7.77
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 2.28
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 2.33
0.159 0.099 0.256 53 / 476 512 / 695
0.01 0.1 1 10 100
Favours experimental Favours control
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
thgiewlatnemirepxElortnoCtimiltimiloitar
Anagnostou 2014 0.017 0.001 0.277 0 / 46 24 / 39 2.46
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 2.50
Camini 2009 0.183 0.013 2.528 0 / 3 7 / 10 2.68
Camini 2015 0.011 0.000 1.952 0 / 14 16 / 17 0.81
Dello Lacono 2013 1.000 0.022 45.635 1 / 10 1 / 10 1.43
Enrique 2005 0.218 0.030 1.588 1 / 11 5 / 12 4.03
Escudero 2015 0.035 0.005 0.238 1 / 31 28 / 30 4.18
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 8.89
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 7.64
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 10.03
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 2.58
Lee 2013 0.045 0.003 0.688 0 / 12 14 / 16 2.52
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 2.43
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 10.03
Meglio 2013 0.250 0.070 0.897 2 / 10 8 / 10 6.64
Morisset 2007b 0.692 0.468 1.023 18 / 39 34 / 51 11.40
Pajno 2010 0.048 0.003 0.746 0 / 15 10 / 15 2.49
Patriarca 1998 0.055 0.004 0.826 0 / 10 12 / 14 2.53
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 2.58
Staden 2007 0.722 0.347 1.504 7 / 21 12 / 26 9.61
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 2.55
0.209 0.129 0.340 52 / 391 335 / 490
0.01 0.1 1 10 100
Favours experimental Favours control
A
B
Figure 2 (a) Risk ratios (RR) of desensitization following oral
immunotherapy (OIT) or sublingual immunotherapy (SLIT) vs controls
(random-effects model). 2a: Heterogeneity: s2 = 0.617; v2 = 62.845,
df = 26 (P < 0.0001); I2 = 59%; Test for overall effect: Z = 7.582
(P < 0.0001). 2b: Heterogeneity: s2 = 0.498; v2 = 47.608, df = 20
(P < 0.0001); I2 = 58%; Test for overall effect: Z = 6.318
(P < 0.0001). 2c: Heterogeneity: s2 = 0.262; v2 = 23.078, df = 16
(P < 0.112); I2 = 31%; Test for overall effect: Z = 7.406 (P < 0.0001).
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• Subgroup analysis based on the type of AIT protocol (con-
ventional vs rush) also showed a substantial average risk
reduction for both methods (RR, conventional proto-
col = 0.12, 95%CI 0.07, 0.21) (23–27, 30, 32–35, 38, 40, 43,
44, 46, 47, 49–52) (RR, rush = 0.33, 95%CI 0.16, 0.65) (29,
31, 36, 37, 39, 41, 48) (see Appendix S5: Figs S7 and S8).
• Subgroup analyses of types of allergen demonstrated that
in 13 trials investigating CMA, 11 HEA and four peanut
allergy OIT/SLIT substantially reduced the risk of desen-
sitization to CMA, HEA and peanut allergy (RR
CM = 0.12, 95% CI 0.06, 0.25) (25, 35–37, 39–41, 43, 44,
47–51) and (RR HE = 0.22, 95% CI 0.11, 0.45) (24, 26,
27, 30, 33, 38, 39, 41, 44, 50, 51) and (RR peanut = 0.11,
95% CI 0.04, 0.31) (23, 32, 34, 46) (see Appendix S5: Figs
S9–S11). A sensitivity analysis of the 17 OIT and four
SLIT RCTs found a substantial average risk reduction
(RR OIT = 0.18, 95% CI 0.10, 0.32) (23–27, 30, 33, 35–
41, 43, 44, 46) and (RR SLIT = 0.31, 95% CI 0.13, 0.76)
(29, 31, 32, 34) (see Appendix S5: Figs S12 and S13).
The Funnel plot revealed evidence of potential publication
bias with fewer smaller, negative studies than expected (see
Fig. 5).
Sustained unresponsiveness post-discontinuation of AIT
There were seven OIT RCTs (24, 26, 30, 33, 42, 44, 45)
and one OIT CCT (52) that investigated the longer-term
effects of AIT between two weeks and 36 months after dis-
continuation of AIT (see Table 1 and Appendix S2:
Table S1). Meta-analysis suggested, but did not confirm the
benefits of OIT (RR = 0.29, 95% CI 0.08, 1.13) (24, 26, 30,
44) (see Fig. 6).
The Funnel plot also revealed evidence of potential publi-
cation bias with fewer smaller, negative studies than expected
(see Fig. 7).
Disease-specific quality of life
Only one OIT RCT reported disease-specific QoL of patients
and their families (23). This study used a validated question-
naire for parents, the Food Allergy Quality of Life Question-
naire Parent Form (FAQLQ-PF); however, no comparative
results between OIT and the control group were reported at
the end of the first phase of the study. Results are reported
for the end of the second phase of the study at which time
the control group had also received OIT.
Secondary outcomes
Safety
Systemic reactions. Data on the occurrence of systemic
adverse reactions during AIT were available from 25 trials
(23–27, 29–31, 33, 35, 36, 39, 40, 42–51) (Table 1). However,
there were different formats of reporting systemic reactions
between trials, and we were therefore only able to pool data
from seven studies (26, 29, 31, 35, 40, 46, 49). Meta-analyses
of not experiencing a systemic reaction were higher in those
receiving control: RR = 1.09, 95% CI 1.00, 1.19) (see Fig. 8)
(26, 29, 31, 35, 40, 46, 49).
Subgroup analysis demonstrated that the risk of
experiencing a systemic reaction was higher in those receiving
OIT (RR of not experiencing a reaction in controls = 1.16,
95% CI 1.03, 1.30) (26, 35, 40, 46, 49). In contrast, data from
two SLIT studies showed no difference between arms (RR of
not experiencing a reaction in controls = 0.98, 95% CI 0.85,
1.14) (29, 31) (see Appendix S5: Figs S14 and S15).
Sensitivity analysis excluding all trials judged to be at high
risk of bias after OIT or SLIT demonstrated either a border-
line difference (RR of not experiencing a reaction in con-
trols = 1.10, 95% CI 0.99, 1.23) (26, 31, 40, 46, 49) or a
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
thgiewlatnemirepxElortnoCtimiltimiloitar
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 2.95
Camini 2015 0.011 0.000 1.952 0 / 14 16 / 17 0.89
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 14.43
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 11.55
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 17.43
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 5.40
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 3.06
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 2.87
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 2.98
Marnez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 3.06
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 17.45
Pajno 2010 0.048 0.003 0.746 0 / 15 10 / 15 2.93
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 2.96
Patriarca 2007 0.054 0.004 0.806 0 / 10 36 / 42 3.01
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 3.05
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 2.95
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 3.01
0.150 0.091 0.248 23 / 283 367 / 477
0.01 0.1 1 10 100
Favours experimental Favours control
C
Figure 2 Continued.
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significant difference in the rate of systemic reactions between
the two arms after OIT (RR of not experiencing a reaction in
controls = 1.17, 95% CI 1.03, 1.33) (26, 40, 46, 49) (see
Appendix S5: Figs S16 and S17).
A subgroup analysis of CMA trials found that the risk of
experiencing a systemic reaction was higher in the AIT arm
(RR of not experiencing a reaction in controls = 1.19, 95% CI
1.03, 1.37) (35, 40, 49) (see Appendix S5: Fig. S18). Subgroup
analysis of systemic reactions during OIT from five children’s
studies to cow’s milk, egg or peanut showed a significant differ-
ence between the two arms; however, the pooled data from the
two studies with adult populations using SLIT for peach or
hazelnut allergy found no clear evidence of a difference in
systemic reactions between the treatment arms and the control
arms (RR of not experiencing a reaction in controls, chil-
dren = 1.16, 95% CI 1.03, 1.30) (26, 35, 40, 46, 49) and (RR of
not experiencing a reaction in controls, adult = 0.98, 95% CI
0.85, 1.14) (29, 31). The lack of a significant effect in adults
may reflect a lack of precision (as the point estimate suggests
benefit), which in turn is a function of the paucity of large trials
in adult populations (see Appendix S5: Figs S19 and S20).
Local reactions
Data on occurrence of local adverse reactions during AIT
(minor oropharyngeal/gastrointestinal/ perioral rash) were
available from 28 trials (23–31, 33, 35–51) (see Table 1).
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
thgiewlatnemirepxElortnoCtimiltimiloitar
Enrique 2005 0.218 0.030 1.588 1 / 11 5 / 12 15.08
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 35.88
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 30.23
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 9.47
Patriarca 2007 0.054 0.004 0.806 0 / 10 36 / 42 9.33
0.257 0.103 0.641 9 / 67 80 / 122
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Risk ratios (RR) of desensitization as assessed by double-blind, placebo-controlled food challenge in SLIT vs controls (random-
effects model). Heterogeneity: s2 = 0.41; v2 = 6.80, df = 4 (P < 0.147); I2 = 41%; Test for overall effect: Z = 2.91 (P < 0.004).
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
thgiewlatnemirepxElortnoCtimiltimiloitar
Anagnostou 2014 0.017 0.001 0.277 0 / 46 24 / 39 3.04
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 3.08
Camini 2009 0.183 0.013 2.528 0 / 3 7 / 10 3.28
Camini 2015 0.011 0.000 1.952 0 / 14 16 / 17 1.06
Dello Lacono 2013 1.000 0.022 45.635 1 / 10 1 / 10 1.83
Escudero 2015 0.035 0.005 0.238 1 / 31 28 / 30 4.86
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 9.77
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 4.92
Lee 2013 0.045 0.003 0.688 0 / 12 14 / 16 3.11
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 3.01
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 3.11
Marnez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 3.18
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 9.78
Meglio 2013 0.250 0.070 0.897 2 / 10 8 / 10 7.15
Morisset 2007b 0.692 0.468 1.023 18 / 39 34 / 51 10.70
Pajno 2010 0.048 0.003 0.746 0 / 15 10 / 15 3.07
Patriarca 1998 0.055 0.004 0.826 0 / 10 12 / 14 3.12
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 3.09
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 3.17
Staden 2007 0.722 0.347 1.504 7 / 21 12 / 26 9.48
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 3.08
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 3.13
0.135 0.076 0.237 44 / 409 432 / 573
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Risk ratios (RR) of desensitization as assessed by double-blind placebo-controlled food challenge in OIT v. controls (random-effects
model). Heterogeneity: s2 = 0.735; v2 = 56.047, df = 21 (P < 0.0001); I2 = 62%; Test for overall effect: Z = 6.967 (P < 0.0001).
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However, there were different formats of reporting reactions
between trials, and we were therefore only able to pool data
from nine studies. Meta-analyses of local reactions obtained
from these nine trials demonstrated that AIT was associated
with an increased risk of local reactions (RR of not
experiencing a reaction in controls 2.12, 95% CI 1.50, 3.0)
(24, 26, 28, 35, 37–40, 49) (see Fig. 9).
Subgroup analysis of local adverse events demonstrated
higher risk of reactions in those receiving OIT (RR of not
experiencing a reaction in controls = 2.14, 95% CI 1.47,
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Figure 7 Funnel plot showing: risk ratios (RR) of persisting food allergy after OIT or SLIT (only RCTs).
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
thgiewlatnemirepxElortnoCtimiltimiloitar
65.5104/1151/0187.1700.0111.02102skruB
24.2271/541/1448.1230.0342.05102itinimaC
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0.292 0.076 1.126 9 / 81 36 / 113
0.01 0.1 1 10 100
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Figure 6 Risk ratios (RR) of sustained unresponsiveness as assessed by double-blind, placebo-controlled food challenge in OIT v. controls (ran-
dom-effects model). Heterogeneity: s2 = 1.043; v2 = 7.044, df = 3 (P < 0.071); I2 = 57%; Test for overall effect: Z = 1.788 (P < 0.074).
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Figure 5 Funnel plot showing: risk ratios (RR) of persisting food allergy after OIT or SLIT.
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3.12) (24, 26, 37–40, 49) (see Appendix S5: Fig. S21). A fur-
ther sensitivity analysis excluding all trials judged to be at
high risk of bias also showed an increased risk of local reac-
tions in the treatment arms compared with the control arms
(RR of not experiencing a reaction in controls = 2.58, 95%
CI 1.43, 3.02) (24, 26, 37, 40, 49) (see Appendix S5:
Fig. S22). Local reactions during OIT from only RCTs sub-
group analysis demonstrated higher risk of local reactions in
the AIT group (RR of not experiencing a reaction in con-
trols = 2.08, 95% CI 1.43, 3.02) (24, 26, 35, 37–40) (see
Appendix S5: Fig. S23). Another subgroup analysis of local
reactions during OIT for CMA from either RCTs and CCTs
or only RCTs also demonstrated increased risk of having
local reactions in the AIT group (from RCTs and CCTs, RR
of not experiencing a reaction in controls = 3.49, 95% CI
1.89, 6.43) and (35, 37, 39, 40, 49) (from RCTs, RR of not
experiencing a reaction in controls = 3.29, 95% CI 1.50,
7.23) (35, 37, 39, 40) (see Appendix S5: Figs S24 and S25).
Local reactions during OIT for HEA also found an increased
risk of local reactions in the AIT arm (RR of not experienc-
ing a reaction in controls = 1.55, 95% CI 1.09, 2.22) (24, 26,
38, 39) (see Appendix S5: Fig. S26).
The effect of the AIT protocol (conventional vs rush) on
the occurrence of local reactions during the treatment was
available only from OIT trials. Both, conventional and rush
AIT protocols demonstrated an increased risk of local reac-
tions in the treatment arm compared with the controls (RR
of not experiencing a reaction in controls, conven-
tional = 2.58, 95% CI 1.46, 4.55) (24, 26, 35, 38, 40, 49) (RR
of not experiencing a reaction in controls, rush = 2.23, 95%
CI 0.57, 8.80) (37, 39) (see Appendix S5: Figs S27 and S28).
Health economic analysis
None of the studies reported data on cost-effectiveness.
Discussion
Summary of main findings
This systematic review and meta-analysis has found evidence
that AIT may be effective in raising the threshold of reactiv-
ity to a range of foods in patients with IgE-mediated food
allergy whilst receiving (i.e. desensitization) and post-discon-
tinuation of AIT. This evidence comes mainly from studies
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
rao limit limit Control Experimental weight
Burks 2012 3.556 1.897 6.665 12 / 15 9 / 40 10.99
Camini 2015 1.123 0.912 1.382 14 / 14 15 / 17 16.21
Dupont 2010 1.250 0.656 2.383 6 / 8 6 / 10 10.78
Lee 2013 6.000 1.576 22.844 9 / 12 2 / 16 4.83
Mansouri 2007 4.500 1.972 10.270 13 / 13 4 / 20 8.71
Martorell 2011 4.692 2.366 9.308 30 / 30 6 / 30 10.29
Meglio 2013 3.000 1.251 7.194 10 / 10 3 / 10 8.21
Morisset 2007b 1.154 1.027 1.297 39 / 39 44 / 51 16.88
Pajno 2010 1.824 1.141 2.914 15 / 15 8 / 15 13.09
2.121 1.500 2.999 148 / 156 97 / 209
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 9 Safety data – absence of local reactions during OIT or EPIT for food allergy. RR, risk ratio (random-effects model). Heterogeneity:
s2 = 0.182; v2 = 48.412, df = 8 (P < 0.0001); I2 = 83%; Test for overall effect: Z = 4.253 (P < 0.0001).
Study name Stascs for each study Events / Total Risk rao and 95% CI
Risk Lower Upper Relave 
rao limit limit Control Experimental weight
Camini 2015 1.200 0.939 1.534 14 / 14 14 / 17 13.24
Enrigue 2005 0.992 0.770 1.277 10 / 11 11 / 12 12.48
Fernandez-Rivas 2009 0.974 0.812 1.167 17 / 19 34 / 37 24.24
Lee 2013 1.127 0.900 1.412 12 / 12 14 / 16 15.73
Mansouri 2007 1.227 0.961 1.568 13 / 13 16 / 20 13.30
Pajno 2010 1.240 0.943 1.631 15 / 15 12 / 15 10.65
Varshney 2011 0.993 0.753 1.312 8 / 9 17 / 19 10.36
1.089 0.996 1.190 89 / 93 118 / 136
0.5 1 2
Favours experimental Favours control
Figure 8 Safety data – absence of systemic reactions during OIT or SLIT for food allergy. RR, risk ratio (random-effects model). Hetero-
geneity: s2 = 0.0001; v2 = 4.87, df = 6 (P < 0.56); I2 = 0%; Test for overall effect: Z = 1.86 (P < 0.06).
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in children, and it is therefore still unclear if AIT is effec-
tive for adults. Pooling of the safety data demonstrated an
increased risk of local and systemic reactions with AIT.
No fatalities were reported during AIT. Only one study
assessed QoL (23), which reported no comparative results
between OIT and the control group. We found no data
investigating the cost-effectiveness of AIT in patients with
food allergy.
Strengths and limitations of this work
We believe that this systematic review is the most robust
investigation undertaken to date to support the use of AIT
in children and adults with food allergy (53–60). A key
strength of our systematic review was the comprehensiveness
of the searches. We carefully identified and scrutinized the
characteristics of all possible terms, including MeSH,
EMTREE and free keywords for different types of food
allergy and AIT. In addition, we encompassed all available
bodies of evidence from all randomized and NRS, with a
range of planned subgroup and sensitivity analyses.
The main limitations of this systematic review stem from
the heterogeneity of included populations, interventions,
outcomes, diversity of AIT protocols and treatment modali-
ties, and definition of outcomes (e.g. adverse reactions).
Due to the heterogeneity of studies, the meta-analyses need
to be interpreted with caution. In an attempt to account
for this heterogeneity, we undertook random-effects meta-
analyses which produce more conservative assessments of
benefits than would have been obtained using fixed-effects
meta-analyses. That said, this is an area that will warrant
further exploration of the possible sources of heterogeneity
in follow-on work. We were also limited by the lack of
data on long-term adverse outcomes (e.g. eosinophilic
esophagitis) and lack of data on cost-effectiveness. Studies
which were published after our cut-off date 31st March
2016 are not included in this review which may have pro-
vided additional evidence to support the effectiveness and
safety of OIT (61).
Conclusions
We found that AIT may be effective in raising the threshold
of reactivity to a range of foods in patients with IgE-
mediated food allergy whilst receiving (i.e. desensitization)
and post-discontinuation of AIT, but was associated with an
increased risk of local and systemic adverse events. Future
trials need in particular to investigate the effectiveness of
AIT in adults, understand the impact of AIT on disease-
specific QoL of patients and family members, and establish
the cost-effectiveness of AIT for food allergy.
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